The serum concentration of Trichlormethiazide can be increased when it is combined with Chlorphenoxamine. The metabolism of Paritaprevir can be decreased when combined with Boceprevir. Harmaline may increase the hypotensive activities of Lercanidipine. Furazolidone may increase the anticholinergic activities of Doxylamine. Indomethacin may increase the anticoagulant activities of Dextran 40. The serum concentration of Estradiol can be decreased when it is combined with Lisinopril. The serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril. The risk or severity of adverse effects can be increased when Lacidipine is combined with Atorvastatin. The metabolism of Estrone can be decreased when combined with Diltiazem. The metabolism of Simvastatin can be decreased when combined with Bortezomib. The risk or severity of adverse effects can be increased when Moexipril is combined with Metipranolol. The metabolism of Chlorzoxazone can be decreased when combined with Quinine. The risk or severity of adverse effects can be increased when Lurasidone is combined with Methaqualone. The risk or severity of adverse effects can be increased when Lisuride is combined with Salbutamol. The risk or severity of adverse effects can be increased when Remifentanil is combined with Fosinopril. Flurandrenolide may increase the fluid retaining activities of GLPG-0492. Clonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol. The risk or severity of adverse effects can be increased when Chlormezanone is combined with Tetrodotoxin. The risk or severity of adverse effects can be increased when Methocarbamol is combined with Pizotifen. The metabolism of Primidone can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Methohexital is combined with Canertinib. The metabolism of Naproxen can be decreased when combined with Voriconazole. Phenobarbital may increase the hypotensive activities of Timolol. Rocuronium may increase the arrhythmogenic activities of Proscillaridin. The risk or severity of adverse effects can be increased when Fluocortolone is combined with INGN 225. Netilmicin may increase the respiratory depressant activities of Metocurine Iodide. The serum concentration of Famciclovir can be increased when it is combined with Simeprevir. Lercanidipine may increase the hypotensive activities of Methyldopa. The serum concentration of Tacrolimus can be decreased when it is combined with Tocilizumab. The metabolism of Levodopa can be decreased when combined with Chloroquine. Methyclothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level. Pheniprazine may increase the hypotensive activities of Xylometazoline. The risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid. The serum concentration of Amlodipine can be decreased when it is combined with Deferasirox. The risk or severity of adverse effects can be increased when Perindopril is combined with Nabumetone. Polythiazide may increase the hypotensive activities of Cilazapril. Sulindac may decrease the antihypertensive activities of Aliskiren. The metabolism of Rosiglitazone can be increased when combined with Carbamazepine. The metabolism of Indomethacin can be decreased when combined with Zucapsaicin. The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Phenylpropanolamine. The risk or severity of adverse effects can be increased when Dexetimide is combined with Opium. The risk or severity of adverse effects can be increased when Ropinirole is combined with Telmisartan. The serum concentration of Tixocortol can be increased when it is combined with Quinestrol. The risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide. The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine. The metabolism of Aliskiren can be decreased when combined with Dronedarone. The serum concentration of Mevastatin can be increased when it is combined with Buprenorphine. Thiopental may increase the hypotensive activities of Nebivolol. Atorvastatin may increase the hypoglycemic activities of Chlorpropamide. The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Parthenolide. The serum concentration of Rosuvastatin can be increased when it is combined with Diethylstilbestrol. The serum concentration of Metoprolol can be increased when it is combined with Cyproterone acetate. Dextropropoxyphene may increase the sedative activities of Pramipexole. The risk or severity of adverse effects can be increased when Reserpine is combined with Loratadine. The serum concentration of Arbekacin can be decreased when it is combined with Nafcillin. The metabolism of Isradipine can be decreased when combined with Darunavir. Adapalene may increase the anticoagulant activities of Desirudin. The therapeutic efficacy of Pentaerythritol Tetranitrate can be decreased when used in combination with Hydroxyprogesterone caproate. The risk or severity of adverse effects can be increased when Prasterone is combined with Rabies virus inactivated antigen, A. Mefloquine may increase the QTc-prolonging activities of Pimozide. The serum concentration of Buspirone can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Sufentanil is combined with Pramocaine. Piroxicam may decrease the antihypertensive activities of Betaxolol. The serum concentration of Triamcinolone can be increased when it is combined with Genistein. The metabolism of Phenformin can be decreased when combined with Cinacalcet. The bioavailability of Clocortolone can be decreased when combined with Magnesium Hydroxide. The risk or severity of adverse effects can be increased when Fospropofol is combined with Levocabastine. Epirizole may decrease the antihypertensive activities of Nebivolol. The bioavailability of Budesonide can be decreased when combined with Sodium bicarbonate. Esmolol may decrease the bronchodilatory activities of Dyphylline. The risk or severity of QTc prolongation can be increased when Quinine is combined with Artemether. The risk or severity of adverse effects can be increased when Thiamylal is combined with Opium. Diazoxide may increase the hypotensive activities of Atenolol. The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone. The risk or severity of adverse effects can be increased when Zofenopril is combined with Nabumetone. Azelastine may decrease the diuretic activities of Furosemide. The therapeutic efficacy of Nateglinide can be decreased when used in combination with Cyproterone acetate. Methylphenidate may decrease the antihypertensive activities of Indapamide. The metabolism of Ethanol can be decreased when combined with Imatinib. Naproxen may increase the nephrotoxic activities of Olsalazine. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The metabolism of Metronidazole can be decreased when combined with Sulfisoxazole. The risk or severity of adverse effects can be increased when Sevoflurane is combined with Methylphenobarbital. The risk or severity of adverse effects can be increased when Nabumetone is combined with Betamethasone. The serum concentration of Methallenestril can be decreased when it is combined with Amprenavir. The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Masoprocol. Salicylamide may decrease the antihypertensive activities of Levobunolol. The risk or severity of adverse effects can be increased when Tolmetin is combined with Naftifine. The risk or severity of adverse effects can be increased when Piroxicam is combined with Oxyphenbutazone. Ketanserin may increase the hypotensive activities of Perindopril. The metabolism of Pinaverium can be increased when combined with Pentobarbital. Mycophenolate mofetil may decrease the excretion rate of Netilmicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine. Colesevelam can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy. Esmolol may increase the hypoglycemic activities of Glimepiride. Bromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Secobarbital may increase the hypotensive activities of Apomorphine. The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolate mofetil. The risk or severity of adverse effects can be increased when Sulconazole is combined with Rosuvastatin. The risk or severity of adverse effects can be increased when Clofarabine is combined with Pindolol. The risk or severity of adverse effects can be increased when Irbesartan is combined with Nesiritide. The risk or severity of adverse effects can be increased when Vinpocetine is combined with Magnesium Hydroxide. The risk or severity of adverse effects can be increased when Acemetacin is combined with Fluocinolone Acetonide. The serum concentration of Ivacaftor can be increased when it is combined with Nelfinavir. Secobarbital may increase the hypotensive activities of Prazosin. Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine. The metabolism of Irbesartan can be decreased when combined with Gemfibrozil. The risk or severity of adverse effects can be increased when Ondansetron is combined with Efavirenz. The metabolism of Tamoxifen can be decreased when combined with Lidocaine. The risk or severity of adverse effects can be increased when Tolmetin is combined with Rimexolone. The therapeutic efficacy of Beraprost can be decreased when used in combination with Bufexamac. The serum concentration of Rolapitant can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Quinapril is combined with Ketoprofen. Etanercept may increase the anticoagulant activities of Troxerutin. The risk or severity of adverse effects can be increased when Pentolinium is combined with Buprenorphine. The metabolism of Methoxyflurane can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Linagliptin is combined with Fosinopril. Mianserin may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital. The risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine. Tolazoline may increase the hypotensive activities of Captopril. Methylene blue may increase the hypotensive activities of Hydrochlorothiazide. Pentobarbital may increase the hypotensive activities of Tolazoline. The risk or severity of adverse effects can be increased when Sitagliptin is combined with Enalapril. The metabolism of Ibuprofen can be increased when combined with Aprepitant. Carbaspirin calcium may decrease the excretion rate of Idarubicin which could result in a higher serum level. The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Drospirenone. Adapalene may increase the anticoagulant activities of Protein S human. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon. The metabolism of Norgestrel can be decreased when combined with Ranolazine. The risk or severity of adverse effects can be increased when Methysergide is combined with Cortisone acetate.